Cultivating Policy from Cell Types

For better or worse, stem cell science has become inextricably married to stem cell politics. Policymakers who oppose public financing of embryonic stem cells have used recent adult stem cell findings to argue for a dismissal of the NIH stem cell guidelines (see "On the Brink," page 1). The guidelines, finalized last summer during the Clinton administration, call for funding the use, but not derivation, of human embryonic stem cells (ESCs); the pro-life Bush administration appears ready to ban t

Written byEugene Russo
| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share

"I don't think you could find anybody in this field who thinks you should abandon stem cell or embryonic research--yet," comments adult stem cell researcher Diane Krause, an assistant professor of laboratory medicine and pathology at the Yale University School of Medicine. "We all agree that we'd rather not have to deal with the ethical quagmire. But at this point we'll just be hurting our ability to progress if we stop the research."

"There will be questions you can address with adult stem cells, and questions you address with ES cells. They complement each other," says James Thomson, a developmental biologist at the University of Wisconsin, Madison and the leader of one of two groups who were the first to culture human ESCs.2 "And, if you do both, both fields will actually go much faster." Right now, says Thomson, the adult versus embryonic stem cell "debate" is political rather than ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies